Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments, and Histone Deacetylase Inhibitors Research.
Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia
10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed <i>FLT3</i> Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
AML-591 Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study
Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms
Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin
PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY
PS968 GENETIC LANDSCAPE OF FLT3‐MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE)
Functional genomic landscape of acute myeloid leukaemia
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial
Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)
Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia
Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality